PRX OTC

Drug Profile

PRX OTC

Alternative Names: PRX-OTC

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator PhaseRx
  • Class
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inborn urea cycle disorders

Most Recent Events

  • 28 Nov 2016 PRX OTC receives Orphan Drug status for Inborn urea cycle disorders (ornithine transcarbamylase deficiency) in USA
  • 28 Nov 2016 PhaseRx plans to file an IND application with the US FDA in USA for Inborn urea cycle disorders (ornithine transcarbamylase deficiency) by the end of 2017
  • 08 Nov 2016 Preclinical pharmacodynamics and adverse events data released by PhaseRx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top